LU, CHRIS XIANGYANG,HU, SHOU-IH,KNEISSEL, MICHAELA,HALLEUX, CHRISTINE
申请号：
NZ57823508
公开号：
NZ578235A
申请日:
2008.01.30
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Provided is the use of a composition comprising a modulator of a sclerostin-binding partner in the manufacture of a medicament for treatment of a pathological disorder, wherein the sclerostin-binding-partner is LRP4 and wherein the modulator is an antibody or a functional protein comprising an antigen-binding portion of said antibody specifically binding to LRP4, and wherein said antibody or functional protein comprising an antigen binding portion of said antibody inhibits binding of sclerostin to LRP4, and wherein said pathological disorder is an aberrant bone mineral density disorder selected from osteoporosis or sclerosteosis.
